妊娠期接种新型冠状病毒感染(COVID-19)疫苗加强针的安全性:疫苗不良事件报告系统分析
研究检索2021年9月22日至2022年3月24日疫苗不良事件报告系统(VAERS)中妊娠期接种mRNA COVID-19疫苗加强针的不良事件报告,共323例,其中严重报告72例(22.3%),1例新生儿死亡,无孕产妇死亡;死胎和早产报告率低于背景率,非妊娠特异性不良事件比例与同期接种基础系列者相当。结论认为加强针安全性与已发表的基础系列接种报告相当。
要点
- VAERS共收到323例妊娠期接种mRNA COVID-19疫苗加强针的不良事件报告,其中严重报告72例(22.3%)。
- 妊娠特异性结局包括自然流产56例(17.3%)、阴道出血8例(2.5%)、死胎5例(1.5%)、子痫前期4例(1.2%)、早产2例(0.6%)。
- 死胎和早产的报告率低于背景率,非妊娠特异性不良事件比例与同期基础系列接种者相当。
核心结论
- VAERS中妊娠期接种mRNA COVID-19疫苗加强针的报告显示,其安全性特征与已发表的妊娠期基础COVID-19疫苗接种后报告相当。
研究设计与样本
- 研究检索VAERS(全国自愿报告系统)中2021年9月22日至2022年3月24日美国妊娠期接种mRNA COVID-19疫苗加强针的不良事件报告,由临床医生审查报告和可用病历。
主要发现
- VAERS共收到323例妊娠期接种COVID-19疫苗加强针的不良事件报告,其中BNT162b2(辉瑞-BioNTech)178例(55.1%),mRNA-1273(莫德纳)145例(44.9%)。
- 72例(22.3%)报告被编码为严重;报告1例新生儿死亡,无孕产妇死亡。
- 妊娠特异性结局包括自然流产(妊娠20周前)56例(17.3%)、阴道出血8例(2.5%)、死胎(妊娠20周及以上)5例(1.5%)、子痫前期4例(1.2%)、早产2例(0.6%)。
- 死胎和早产的报告率低于背景率;报告新生儿不良事件10例,包括2例出生缺陷报告。
- 非妊娠特异性不良事件207例(64.1%),多为全身性(如头痛、疲劳)和局部反应,其比例与同期VAERS中妊娠期接种基础COVID-19疫苗系列者相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate and summarize reports to the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system, in pregnant people who received a booster dose of mRNA coronavirus disease 2019 (COVID-19) vaccine. METHODS: We searched VAERS for U.S. reports of adverse events in pregnant people who received a booster dose of an mRNA COVID-19 vaccine from September 22, 2021, to March 24, 2022. Clinicians reviewed reports and available medical records. RESULTS: The Vaccine Adverse Event Reporting System received 323 reports of adverse events in pregnant people who received a booster dose of COVID-19 vaccine; 178 (55.1%) after BNT162b2 from Pfizer-BioNTech and 145 (44.9%) after mRNA-1273 from Moderna. Seventy-two (22.3%) reports were coded as serious. One neonatal death was reported, but no maternal deaths occurred. Pregnancy-specific outcomes included 56 (17.3%) spontaneous abortions (before 20 weeks of gestation), eight (2.5%) episodes of vaginal bleeding, five (1.5%) stillbirths (at or after 20 weeks of gestation), four (1.2%) episodes of preeclampsia, and two (0.6%) preterm deliveries. Reporting rates for stillbirth and preterm delivery were below background rates. Ten instances of adverse events in neonates were reported, which included two reports of birth defects. Non-pregnancy-specific adverse events (n=207; 64.1%) were mostly systemic (eg, headache, fatigue) and local reactions and occurred in proportions comparable with those seen in pregnant people who received the primary COVID-19 vaccination series and reported to VAERS during the same period. CONCLUSION: Review of reports after a booster dose of mRNA COVID-19 vaccine in pregnant people in VAERS found their safety profile was comparable with that of published reports after primary COVID-19 vaccination in pregnant people.
引用
- Moro PL, Olson CK, Zhang B, et al. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System. Obstet Gynecol. 2022. PMID: 35926203. doi:10.1097/AOG.0000000000004889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。